21st EGA Annual Conference / 9-11 June 2015 / Berlin
Biosimilar medicines: an opportunity for healthcare
Since 2006, biosimilar medicines have generated more than 400 Million patient days of clinical experience. Healthcare professionals and patients can be confident that authorised biosimilar medicines have been demonstrated to be of high quality and as safe and efficacious as their reference product. So what are biosimilar medicines?
2015 EBG Biosimilars Conference focuses on enhancing stakeholder understanding and acceptance of biosimilars
London, 23 April 2015 - Celebrating the 10th anniversary of the EU biosimilars framework, around 280 delegates from 36 countries will join the 13th EGA-European Biosimilars Group Conference in London to discuss key topics related to biosimilar medicines. The main topics at the conference will include a review of the impact of biosimilars on improving access and supporting the sustainability of healthcare systems as well as key regulatory and market developments.
FRENCH GOVERNMENT TO BOOST ACCESS TO HIGH QUALITY GENERIC MEDICINES
Brussels, 31 March 2015 - The European Generic and Biosimilar medicines Association (EGA) welcomes the new French national action plan to promote generic medicines presented by the French Ministry of Health last week. This plan is essential to generate higher generic medicine growth as it currently only accounts for 32% of the reimbursement market in France – a level far below many of France’s European partners.
11th EGA ANNUAL LEGAL AFFAIRS FORUM PROMOTES HEALTHCARE SUSTAINABILITY AND JOB CREATION IN EUROPE
Brussels, 26 March 2015 - The European Generic and Biosimilar medicines Association holds its 11th Legal Affairs Forum today and tomorrow in Brussels. This event brings together company executives, regulators, EU authorities and other industry leaders to discuss key legal issues impacting the generic and biosimilar medicines industries.
30 April 2015
09 - 11 June 2015
Leading on health equality and sustainable access to medicines for European patients More details available here
EGA Vision 2015, the Way forward for more Efficient Regulatory Environment for Generic and Biosimilar Medicines
GfK Final Report- Factors Supporting a Sustainable European Biosimilar Medicines Market
GfK Final Report - Factors Supporting a Sustainable European Biosimilar Medicines Market GfK Final Report- Factors Supporting a Sustainable European Biosimilar Medicines Market
Biosimilars: The science of extrapolation
Martina Weise, Pekka Kurki, Elena Wolff-Holz, Marie-Christine Bielsky, and Christian K. Schneider, Biosimilars: The science of extrapolation, Blood, 20 November 2014, Volume 124, NUMBER 22 Biosimilars_the_science_of_extrapolation.pdf
(free download for non-industry stakeholders only)
EGA Biosimilars Handbook
EGA Biosimilars Handbook
English version EGA_BIOSIMILARS_handbook_en.pdf
German version EGA_Biosimilars_ProGen-Biosimilars-A5-RZ-web_ende.pdf
Italian version EGA_BIOSIMILARS_IT.pdf
Spanish version EGA_BIOSIMILARS_INT_Spain.pdf